9166 Federal Register / Vol. 89, No. 28 / Friday, February 9, 2024 / Notices 

1National Forensic Laboratory Information 

System (NFLIS). (2022). NFLIS-Drug 2022 Annual 

Report. U.S. Department of Justice, Drug 

Enforcement Agency, Diversion Control Division. 

2022 NFLIS-Drug Annual Report.pdf. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Todd Everett White, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–3962, todd.white@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Program 

Project: Neuroscience and Substance use. 

Date: March 12, 2024. 

Time: 12:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Anne-Sophie Marie Lucie 

Wattiez, Ph.D., Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Bethesda, MD 20892, (301) 594–4642, annesophie.wattiez@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Bioengineering, Surgery, 

Anesthesiology, and Trauma. 

Date: March 13, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Donald Scott Wright, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5108, 

MSC 7854, Bethesda, MD 20892, (301) 435– 

8363, wrightds@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Epidemiology and Population 

Sciences. 

Date: March 13–14, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Rebecca I. Tinker, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20817, (301) 435–0637, tinkerri@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: February 6, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–02696 Filed 2–8–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Closed 

Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Eye Institute 

Special Emphasis Panel; BRAIN Initiative: 

New Concepts and Early-Stage Research for 

Recording and Modulation in the Nervous 

System (R21). 

Date: March 19, 2024. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Eye Institute, 6700 

Rockledge Dr., Bethesda, MD 20817. 

Contact Person: Brian Hoshaw, Ph.D., 

Designated Federal Official, Division of 

Extramural Research, National Eye Institute, 

National Institutes of Health, 6700 B 

Rockledge Dr., Rockville, MD 20892, 301– 

451–2020, hoshawb@mail.nih.gov. 

Name of Committee: National Eye Institute 

Special Emphasis Panel; Conference Grant 

Applications (R13). 

Date: April 15, 2024. 

Time: 10:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Eye Institute, 6700 

Rockledge Dr., Bethesda, MD 20817. 

Contact Person: Jeanette M. Hosseini, 

Ph.D., Scientific Review Officer, Division of 

Extramural Research, National Eye Institute, 

National Institutes of Health, 6700 B 

Rockledge Drive, Bethesda, MD 20892, 301– 

451–2020, jeanetteh@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.867, Vision Research, 

National Institutes of Health, HHS) 

Dated: February 5, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–02653 Filed 2–8–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Notice of Meeting 

Pursuant to Public Law 92–463, 

notice is hereby given that the 

Substance Abuse and Mental Health 

Services Administration’s (SAMHSA) 

Center for Substance Abuse Prevention’s 

(CSAP) Drug Testing Advisory Board 

(DTAB) will convene via web 

conference on March 5, 2024, from 10 

a.m. EST to 12:45 p.m. EST. 

The board will meet in open-session 

March 5, 2024, from 10 a.m. EST to 

12:45 p.m. EST to hear presentations 

regarding proposed changes to the 

analyte table including fentanyl 

prevalence, fentanyl immunoassay 

updates, cost and benefits analysis and 

a summary of public comments received 

regarding the proposed changes to the 

HHS Drug Testing Panels. 

Section 8105 of the Fighting Opioid 

Abuse in Transportation Act, included 

in the SUPPORT for Patients and 

Communities Act, required the 

Secretary to determine whether it is 

justified, based on the reliability and 

cost-effectiveness of testing, to revise 

the Mandatory Guidelines for Federal 

Workplace Drug Testing Programs to 

include fentanyl. Section 8105 

additionally required the Secretary to 

consider whether to include any other 

drugs or other substances listed in 

Schedule I and II of Controlled 

Substances Act (CSA). Norfentanyl is a 

metabolite of fentanyl. Because it is also 

an immediate precursor used in the 

illicit manufacture of fentanyl, it is a 

Schedule II substance under the CSA. 

Fentanyl is involved in a large 

proportion of overdose deaths in the 

United States and is therefore an 

important public safety concern. 

Furthermore, fentanyl is increasingly 

used as a stand-alone substance, not in 

conjunction with heroin and other 

substances. According to the National 

Forensic Laboratory Information System 

(NFLIS) 2022 report, fentanyl was the 

3rd most frequently identified drug and 

accounted for 13.81% of all drugs 

reported by forensic laboratories.1

Norfentanyl is an important component 

of identifying people who use fentanyl 

when urine is the specimen matrix. 

Fentanyl has been detected in oral fluid 

in patients receiving pain management 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 28 / Friday, February 9, 2024 / Notices 9167 

services, overdose cases, and driving 

under the influence of drugs (DUID) 

cases. Information provided by HHScertified laboratories in 2023 indicated 

that a majority (84%) of the laboratories 

analyzed non-regulated workplace 

specimens for fentanyl and/or 

norfentanyl, and that all had the ability 

to analyze urine specimens for fentanyl 

with sufficiently sensitive detection 

limits using commercially available 

immunoassay kits and confirmatory test 

instrumentation commonly used in 

HHS-certified laboratories. 

Proposed addition to HHS Drug 

Testing Panels as listed below: 

Urine analyte Initial test 

cutoff 

Confirmation 

cutoff 

Fentanyl ......... 1 ng/mL .... 1.0 ng/mL. 

Norfentanyl .... ................... 1.0 ng/mL. 

Oral fluid 

analyte 

Initial test 

cutoff 

Confirmation 

cutoff 

Fentanyl ......... 1 ng/mL .... 1.0 ng/mL. 

The Department plans to remove 

MDA and methylenedioxymethamphetamine (MDMA) from the 

drug testing panel, because the number 

of positive specimens reported by HHScertified laboratories does not support 

testing all specimens for MDA and 

MDMA in Federal workplace drug 

testing programs. Information provided 

to the Department through the NLCP in 

2021 and 2022 shows the positivity rate 

for MDMA ranges from 0.001 to 0.003%, 

and a review of the results indicate that 

>25% of the positive specimens are 

likely agency blind samples. MDA has 

a lower positivity rate than MDMA and 

both have lower positivity rates than 

phencyclidine (PCP). SAMHSA also 

considered removing PCP but decided 

against this change. While PCP has an 

overall positivity rate nearly as low as 

MDMA, there are regional differences in 

positivity, with some areas of the 

country having much higher rates, so 

PCP remains a regulated test analyte. 

Because MDA and MDMA are Schedule 

I drugs, a Federal agency may test 

specimens for these analytes in 

accordance with Section 3.2 of the 

UrMG and OFMG (i.e., on a case-by-case 

basis for reasonable suspicion or postaccident testing, or routinely with a 

waiver from the Secretary). 

Meeting registration information can 

be completed at https://snacregister.

samhsa.gov/. Web conference and call 

information will be sent after 

completing registration. Meeting 

information and a roster of DTAB 

members may be obtained by accessing 

the SAMHSA Advisory Committees 

website, https://www.samhsa.gov/ 

about-us/advisory-councils/meetings, or 

by contacting the Designated Federal 

Officer, Lisa Davis. 

Committee Name: Substance Abuse 

and Mental Health Services 

Administration, Center for Substance 

Abuse Prevention, Drug Testing 

Advisory Board. 

Dates/Time/Type: March 5, 2024, 

from 10:00 a.m. EST to 12:45 p.m. EST: 

OPEN. 

Place: Virtual. 

To Submit Comments: Requests to 

make public comment during the public 

comment period of the March DTAB 

meeting must be made in writing at least 

7 days prior to the meeting to the 

following email: DFWP@

samhsa.hhs.gov. 

Contact: Lisa S. Davis, M.S, Social 

Science Analyst, Center for Substance 

Abuse Prevention, 5600 Fishers Lane, 

Rockville, Maryland 20857, Telephone: 

(240) 276–1440, Email: Lisa.Davis@

samhsa.hhs.gov. 

Anastasia Flanagan, 

Public Health Advisor, Division of Workplace 

Programs. 

[FR Doc. 2024–02640 Filed 2–8–24; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID: FEMA–2024–0006; OMB No. 

1660–0110] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request; Nonprofit Security 

Grant Program (NSGP) Investment 

Justification & NSGP Prioritization 

Tracker 

AGENCY: Federal Emergency 

Management Agency, Department of 

Homeland Security. 

ACTION: 60-Day notice of extension and 

request for comments. 

SUMMARY: The Federal Emergency 

Management Agency (FEMA), as part of 

its continuing effort to reduce 

paperwork and respondent burden, 

invites the general public to take this 

opportunity to comment on an 

extension of a currently approved 

information collection. In accordance 

with the Paperwork Reduction Act of 

1995, this notice seeks comments 

concerning the Nonprofit Security Grant 

Program (NSGP). The NSGP provides 

funding support for security-related 

enhancements to nonprofit 

organizations that are at high risk of a 

terrorist or other extremist attack. 

DATES: Comments must be submitted on 

or before April 9, 2024. 

ADDRESSES: 

To avoid duplicate submissions to the 

docket, please submit comments at 

www.regulations.gov under Docket ID 

FEMA–2024–0006. Follow the 

instructions for submitting comments. 

All submissions received must 

include the agency name and Docket ID. 

Regardless of the method used for 

submitting comments or material, all 

submissions will be posted, without 

change, to the Federal eRulemaking 

Portal at http://www.regulations.gov, 

and will include any personal 

information you provide. Therefore, 

submitting this information makes it 

public. You may wish to read the 

Privacy Act notice that is available via 

the link in the footer of 

www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: 

Mark Silveira, Branch Chief, FEMA 

Grant Programs Directorate, 

Preparedness Grants Program, 202–786– 

9598 mark.silveira@fema.dhs.gov. You 

may contact the Information 

Management Division for copies of the 

proposed collection of information at 

email address: FEMA-InformationCollections-Management@fema.dhs.gov. 

SUPPLEMENTARY INFORMATION: The 

collection of information for the 

Nonprofit Security Grant Program is 

mandated by sections 2003 and 2004 of 

the Homeland Security Act of 2002 (6 

U.S.C. 604), as amended by section 101, 

Title I of the Implementing 

Recommendations of the 9/11 

Commission Act of 2007 (Pub. L. 110– 

053). These sections mandate that 

applicants submit plans to describe the 

proposed division of responsibilities 

and distribution of funding among the 

local and tribal government in the highrisk urban area; mandate that applicants 

submit information in support of the 

application as the Administrator may 

reasonably require; mandate that 

applicants submit their application to 

each State for review before submission 

of such application to the Department; 

and delineate and describe the actions 

Governors must take if deeming that an 

application is inconsistent with their 

States’ Homeland Security Strategy. 

This program is designed to promote 

coordination and collaboration in 

emergency preparedness activities 

among public and private community 

representatives, State, and local 

government agencies. 


ddrumheller on DSK120RN23PROD with NOTICES1